lifestyle.cleanweb.co

Author: Jaguar Health, Inc.

FDA Feedback Supports Extension Phase for Jaguar Health’s Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

April 29, 2026
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

April 28, 2026
Jaguar Health Strengthens Company’s Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

March 9, 2026
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

March 3, 2026
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health’s Special One-time Stock Dividend

March 2, 2026
Jaguar Health Announces a Special One-time Stock Dividend

February 18, 2026
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

January 22, 2026
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

January 18, 2026
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

January 12, 2026
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

January 8, 2026